FOUNTAIN VALLEY, Calif., Mar. 1, 2016 /PRNewswire-iReach/ -- Larn Hwang*, Kevin Ng**, Wen Wang*, and Vuong Trieu**
Photo - http://photos.prnewswire.com/prnh/20160226/337973LOGO
**Autotelic Inc, Fountain Valley, CA
*Oncotelic Inc, Agoura Hills, CA
Overexpression of transforming growth factor-beta 2 (TGF-b2) is associated with poor prognosis and plays a key role for malignant progression of various tumors by inducing proliferation, metastasis, angiogenesis and immunosuppression. Previously reported P-001 trial of Trabedersen - Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2- was evaluated to determine if treatment with Trabedersen primed the tumors to subsequent chemotherapy.
Trabedersen treatment was characterized by outstanding overall survival (OS) which was not supported by progression-free survival (PFS). The effect was seen primarily when chemotherapies were used as third line after Trabedersen treatment; OS benefit was not observed for the converse- chemotherapies used first followed by Trabedersen. The data support the enhancement of subsequent chemotherapies following Trabedersen treatment suggesting a combination trial of Trabedersen and chemotherapies with sequencing.
Meeting: 3rd St. Gallen International Gastrointestinal Cancer Conference
Location: St. Gallen, Switzerland
Date: Thursday March 10 and Friday March 11, 2016
Title: “Treatment with Trabedersen- an anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies” (poster no. P5)
Authors: L. Hwang*, K. Ng**, W. Wang*, V. Trieu**
Institutions: **Autotelic Inc, Fountain Valley, CA, USA; *Oncotelic Inc, Agoura Hills, CA, USA
The abstract will be published in a supplement issue to the journal “EJC” by Elsevier Publishers and the poster will also be published on Science Direct.
About Trabedersen
Trabedersen, a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) designed to specifically target the human TGF-2 messenger RNA. The Mechanism of Action exploration focuses on target downregulation and immunostimulation. Trabedersen is believed to reverse TGF-'s immunosuppressive effects, rendering the tumor visible to a patient’s immune system and resulting in priming and specific activation of the patient’s anti-tumor immune response. Trabedersen has been tested in Phase l/ll clinical trials against pancreatic cancer and melanoma. Trabedersen has also been tested in clinical trials against brain cancer.
About Oncotelic Inc.
Oncotelic’s lead therapeutic platform is OT-101 (Trabedersen). Oncotelic intends to conduct registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The executives of Oncotelic are a group of pharmaceutical veterans who believe that Trabedersen will present a paradigm shift in the treatment of cancers. More information is available at www.oncotelic.com.
About Autotelic Inc.
Autotelic works through partners to transform how medications are being delivered. The Autotelic Inc. platform is aTherapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. Current dosing schemes result in either too much drug exposure or too little drug exposure because of individual pharmacokinetic variations. The Autotelic pipeline includes TDM devices for management of oncology, hypertension and pain. More information is available at www.autotelicinc.com.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as “assumes,” “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the Trabedersen; and the clinical development and commercial potential of Trabedersen. All such forward-looking statements are based on Oncotelic’s current beliefs and expectations, and should not be regarded as a representation by Oncotelic that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Oncotelic’s businesses, including: the company may require substantial additional funding in order to obtain regulatory approval for and commercialize any products; the risk that delays in the regulatory approval or commercial launch of Trabedersen will enable competitors to develop and bring new competing products to market before the approval, if any, of Trabedersen; the scope and validity of patent protection for Trabedersen as well as Oncotelic’s platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; and additional risks set forth in any of Oncotelic’s public announcements. These forward-looking statements represent Oncotelic’s judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Oncotelic undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Disclosure of Interest:
The authors are employees of Autotelic Inc or Oncotelic Inc.
Media Contact: Larn Hwang Ph.D., Autotelic Inc,, 714-445-0217, info@autotelicinc.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Oncotelic Inc.
